Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease

Inclusion Criteria: COHORT 1 * Is going to receive or has received PROHANCE injection during an MRI examination; * Has CKD with eGFR stably comprised between 30 and 59 mL/min/1.73m2, as calculated from a SCr value obtained from the local laboratory within 24 hours prior to the PROHANCE injection. * Provides written informed consent and is willing to comply with protocol requirements. OR COHORT 2 * Is going to receive or has received PROHANCE injection during an MRI examination; * Has CKD with eGFR below 30 mL/min/1.73m2, as calculated from a SCr value obtained from the local laboratory within 24 hours prior to the PROHANCE injection. * Provides written informed consent and is willing to comply with protocol requirements. Exclusion Criteria: COHORT 1 * Has received a GBCA within the past 12 months prior to inclusion in this study; * Has unstable kidney function; * Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data and achieving study objectives; * Has ever been suspected of, or diagnosed with, NSF prior to the study-specific MRI; * Is unable or unwilling to return for necessary office visits, to be examined by dermatologists or to undergo deep skin biopsy should development of NSF be suspected. OR COHORT 2 * Has received a GBCA within the past 12 months prior to inclusion in this study; * Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data and achieving study objectives; * Has ever been suspected of, or diagnosed with, NSF prior to the study-specific MRI; * Is unable or unwilling to return for necessary office visits, to be examined by dermatologists or to undergo deep skin biopsy should development of NSF be suspected.